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that individual predispositions for developing this cancer may depend on genetic changes, including changes in genes involved in the process of DNA repair, which is responsible for dealing with DNA damages. 4, 5 DNA repair systems play a crucial role in maintaining the genome stability, which include nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), and double-strand break repair (DSBR). 6, 7 Typically, NER is listed as biochemical tool to deal with UV-induced damage such as cyclobutane-pyrimidine dimers and 6-4 pyrimidine-pyrimidone photoproduct. 8 NER process had been reported to contain three steps, including damage recognition, unwinding of DNA and removal of the damaged fragment, and DNA synthesis. 9, 10 Several types of genes are known to be involved in NER, including ERCC1, ERCC4, and ERCC5. 11, 12 Genetic variations in ERCC1, ERCC4, and ERCC5 gene affect repair of bulky DNA lesions, maintenance of genomic stability, and thus affect cancer risk. 13, 14 NER gene polymorphisms have been extensively studied in terms of their associations with cancer risk as well as clinical outcomes in specific cancer types. [15] [16] [17] The previous study had shown that polymorphisms in DNA repair genes involved in nuclear excision repair (NER) could alter the efficacy of DNA repair and thus influence individual susceptibility to colorectal cancer. 18, 19 Although many efforts have been made to explore the role of ERCC1, ERCC4, and ERCC5 polymorphisms in the NER pathway in the development of colorectal cancer, but it is still not identified the underling functional mechanisms between these polymorphisms and the colorectal cancer risk. 20, 21 In our study, we performed a case-control study on 1101 colorectal cancer patients and 1175 matched healthy controls to determine the association between DNA repair gene (ERCC1, ERCC4, and ERCC5) polymorphisms and the risk of colorectal cancer and further reveal the functional mechanisms of CRC risk.
| MATERIAL S AND ME THODS

| Study subjects
In our study, we recruited a total of 1101 newly diagnosed and histologically confirmed colorectal cancer patients, in the Jiangsu province (China) between January 2014 and October 2017. Healthy controls (1175) were randomly selected from the same hospital for physical examination. The controls were genetically unrelated to the colorectal cancer cases. The pathologic stage of colorectal cancer was assessed using the Sixth Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual. All participants signed an informed consent form, and all activities on human subjects were carried out under full compliance with the Helsinki Declaration. The study was approved by the Ethics Committee of Southeast University Affiliated Zhongda Hospital (Nanjing, China).
| DNA extraction and genotyping
Genomic DNA was extracted from whole-blood samples using the RelaxGene Blood DNA System (Tiangen Biotech). The genotypes of the rs6498486, rs3212986, and rs17655 polymorphisms were determined by TaqMan allelic identification assay equipped with A Quant Studio 6 Flex system (Applied Biosystems, Life Technologies). The loading wells without DNA were used as negative controls. 10% samples were randomly selected for verification. The accordance rate was 100%.
| Real-time PCR Assay
Total RNA was isolated from colorectal cancer tissues using Trizol reagent (Invitrogen). SYBR Green Realtime PCR (Toyobo) assay was determined by Quant Studio 6 Flex system (Applied Biosystems, Life Technologies). β-actin was chosen as internal control. Primer sequences were 5'-TCCTCAGTTGAACCTCCGTAT-3' (forward) and 5'-ACCCCTCACTATCATCCATCC-3' (reverse) for ERCC4 and 5'-ATCCGCAAAGACCTGT-3' and 5'-GGGTGTAACGCAACTAAG-3' for β-actin. Each reaction was done in triplicate.
| Immunohistochemistry
Paraffin-embedded sections fixed by formalin were dewaxed in xylene and then hydrated with ethanol gradient. Endogenous peroxidase was blocked with methanol containing 0.3% hydrogen peroxide for 30 minutes. To retrieve antigenicity, sections were boiled in 10 mmol/L citrate buffer (pH 5.8) for 30 minutes in a microwave (800 W). Next, the slices were placed in 1× CB buffer to room temperature, then transferred to TBS solution, and soaked in TBS solution for 5 minutes. Afterward, the sections were incubated at 4°C for 48 hours with primary antibodies specific for ERCC4 diluted at 1:100. After 2 days, sections were rinsed with fresh TBS solution and incubated at room temperature with horseradish peroxidase-linked secondary antibodies for 30 minutes. Finally, the sections were stained with 3,30-diaminobenzidine (DAB) substrate and counterstained with hematoxylin. Images were recorded using a microscope.
ERCC4 IHC was classified using the following scoring scheme proposed: negative or weak, ≤3; moderate, >3 but ≤6; and strong, >6.
| Cell culture
The human colorectal cancer cell line (RKO and HT-29) and HEK293T were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (Sigma, St. Louis), penicillin and streptomycin in 5% CO 2 at 37℃. The cells were periodically detected and verified to be mycoplasma-free. These three cell lines were detected by short tandem repeat analysis and used within 6 months.
| Luciferase assay
293T, RKO, and HT-29 cells were seeded into 6-well plates and cultured for 16-24 h until grown to 50%-60% confluence. The ERCC4 promoter sequence containing rs6498486 A or C allele was constructed into pGL3-basic vector. They were then co-transfected with a firefly luciferase expressing plasmid (2 μg) and internal control vector pRL-SV40 (2 μg) as an internal control, using Lipofectamine 2000 reagent (Invitrogen), in accordance with the manufacturer's protocol. After 48 hours, we measured luciferase activity using a Dual Luciferase Reporter Assay (Promega). The relative luciferase activity was estimated by normalizing firefly luciferase activity to that of Renilla for each assay.
| Statistical analysis
The Hardy-Weinberg equilibrium (HWE) was estimated in controls using the goodness-of-fit chi-square test (χ 2 test). Both t test and χ2 test were applied to describe the frequency distribution of the demographic characteristic and genotype results of the SNPs between the cases and controls. Genotype and allele frequency differences between cases and controls were evaluated using logistic regression analysis, with odds ratios (OR) and 95% confidence intervals (95% CI), adjusted for age and sex. All statistical analyses were conducted using SAS. P value of less than 0.05 was considered statistically significant.
| RE SULT
| Demographic and Characteristic of the study population
The control information on the subjects has been shown previously. 22 The demographic and clinicopathological characteristics of the colorectal cancer cases and healthy controls are exhibited in 
| Relationship between the selected polymorphisms and colorectal cancer susceptibility
The association between the four SNPs and colorectal cancer risk is shown in Table 2 . The genotype distributions in control were in accordance with Hardy-Weinberg equilibrium (P > 0.05). The rs6498486 AC/CC genotypes were associated with decreased colorectal cancer risk (adjusted OR = 0.82, 95% CI = 0.69-0.97). However, no significant differences were observed between the risk of CRC and the rs3212986 and rs17655 polymorphisms.
| Stratified analysis of rs6498486 polymorphism and colorectal cancer risk
Stratified analysis was performed to evaluate the association between the rs6498486 polymorphism and colorectal cancer risk. As shown in Table 3 , the rs6498486 AC/CC genotype suffered a significantly higher risk in the subgroups of Male (adjusted OR = 0.76, 95% CI = 0.61-0.95), negative lymph node metastasis (adjusted OR = 0.80, 95% CI = 0.66-0.99), positive distant metastasis (95% CI = 0.73, 95% CI = 0.58-0.92), and TNM IV (adjusted OR = 0.73, adjusted OR = 0.58-0.92).
| rs6498486 CC genotype decreased the ERCC4 expression levels by reducing the ERCC4 transcriptional activity
On the basis of our previous findings, we found that rs6498486 A > C polymorphism decreased the risk of colorectal cancer. Because rs6498486 polymorphism is located in the ERCC4 promoter region, we speculate that the ERCC4 rs6498486 polymorphism may affect the binding of transcription factors to promoter regions. Therefore, we analyzed the ERCC4 rs6498486 A > C polymorphism promoter region by using a bioinformatics algorithm (AliBaba2). And we found that the rs6498486 A > C polymorphism might alter the binding ability of NF-kB to the rs6498486 mutation region ( Figure 1D ). 
Genotype
TA B L E 2 Association between ERCC4, ERCC1, and ERCC5 polymorphisms and colorectal cancer risk
To further explore whether rs6498486 polymorphism can affect the transcriptional activity of ERCC4, we performed luciferase assay to evaluate rs6498486 transcriptional activity. We constructed two luciferase reporter vectors ( Figure 1E ) contain rs6498486 allele (A or C), which were transient transfected into RKO, HT-29, and 293T cells together with the Renilla luciferase plasmid. As shown in Figure 1F , the plasmid carrying C allele exhibited the significantly reduced luciferase activity than that with A allele in 293T, RKO, and HT-29 cells.
Inspired by luciferase assay, we wondered whether rs6498486 polymorphism could influence the expression level of ERCC4 through affecting the ERCC4 transcription activity. Then, we collected paraffin sections of colorectal cancer (n = 50) for each genotype and performed IHC analysis. The IHC staining of ERCC4 in colorectal cancer tissue with different rs6498486 genotypes was shown in Figure 1A ,B. Results showed that the ERCC4 protein levels were downregulated in the patients carrying the AC/CC genotypes compared with those with the AA genotype. Then, we examined ERCC4 mRNA level in 88 tumor tissues from colorectal cancer patients with different genotypes. Similar to the IHC assay, compared with AA genotype, patients carrying with CC genotype showed a lower ERCC4 mRNA level ( Figure 1C ).
| Expression level of ERCC4 in CRC
To further investigate the potential role of ERCC4 in CRC development, we then assessed the ERCC4 expression in 88 colorectal cancer tissue and adjacent normal tissue. As shown in Figure 2A , compared with adjacent normal tissue, a higher ERCC4 mRNA level was observed in cancer tissue. In conclusion, ERCC4 rs6498486 A > C polymorphism reduced CRC risk by downregulating ERCC4 expression.
| D ISCUSS I ON
In this work, we investigated the association between 3 SNPs (rs6498486, rs3212986, and rs17655) and colorectal cancer Figure 2B ).
Many efforts have been made to investigate the role of ERCC1, ERCC4, and ERCC5 polymorphisms in the development of cancer.
For example, a meta-analysis demonstrated that ERCC1 rs3212986
polymorphism was significantly associated with glioma risk under the following genetic models, and no association was observed between glioma risk and ERCC5 rs17655. 23 However, Hou et al found that rs6498486 polymorphism not associated with risk of colorectal cancer and rs3212986 may be associated with colorectal cancer risk in a Chinese population. 20 In addition, in recently published metaanalyses, Zeng et al 24 suggests that the ERCC5 rs17655 polymorphism might contribute to genetic susceptibility to colorectal cancer.
These results were inconsistent with our studies. This difference may be related to the small sample size and different ethnic backgrounds of previous researches.
Nucleotide excision repair (NER) plays a pivotal role in maintaining the stability and integrity of the genome. 25 And NER process includes steps of damage recognition, damage demarcation and unwinding, damage incision, and new strand ligation. 26, 27 In the NER process, ERCC4 as an important gene could play an indispensable role in varied DNA repair system. 11 XPF (ERCC4) is located on The nuclear factor-kappaB (NF-kB) is a family of regulatory proteins controlling many biological processes, including: proliferation, survival, apoptosis, invasion, and metastasis in many normal and cancerous cell types. [30] [31] [32] When the NF-kb pathway is activated, the released p65/ p50 NF-kB dimers translocate from the cytoplasm to the nucleus where they bind to specific DNA sequences and promote transcription of target genes. 32, 33 The NF-kB signaling pathway has been shown to promote the progression of different cancers, including breast cancer, prostate cancer, pancreatic cancer, and colorectal cancer. 34, 35 In our study, we found that rs6498486 A > C polymorphism may alter the 
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